Anti-SLC34A2 antibody produced in rabbit

Solute carrier family 34 member 2 (SLC34A2) belongs to the solute carrier gene family and is mapped to human chromosome 4p15.2. The gene codes for the type II Na/Pi co-transporter, NaPi2b. The encoded protein contains 690 amino acids. SLC34A2 is mainly localized on cell surfaces as a heavily glycosylated plasma membrane protein.

solute carrier family 34 (sodium phosphate), member 2 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Sodium-dependent phosphate transport protein 2B (NaPi-2b), encoded by solute carrier family 34 member 2 (SLC34A2), is a multi-transmembrane sodium-dependent phosphate transporter. The protein plays a vital role in various cellular functions including transcellular inorganic phosphate absorption, maintenance of phosphate homeostasis, and tumorigenesis. Elevated expression of SLC34A2 is observed in ovarian cancer and papillary thyroid cancer, but decreased expression of the gene is observed in human non-small cell lung carcinomas. In addition, overexpression of SLC34A2 might also be implicated in the development of breast cancer. Hence, this gene might act as a potential therapeutic target and marker for diagnosis of breast cancer. Knockdown of SLC34A2 gene suppress proliferation and invasion of hepatocellular carcinoma (HCC) cells, by inhibiting the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Corresponding Antigen APREST79802

Solution in phosphate buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide.

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.